ClinicalTrials.gg
RecruitingNCT06323031Blink-DoCUpdated Jul 13, 2026

Spontaneous Eye Blinking in Disorders of Consciousness

An observational study in Disorders of Consciousness, sponsored by Fondazione Don Carlo Gnocchi ETS. Recruiting at 8 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Fondazione Don Carlo Gnocchi ETS · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Consciousness Disorders with a site in Italy — 10 open to participants now, 10 under way, 1 of them phase 3. Consciousness Disorders · Italy.

Planned enrollment
6th of 16
70 · median 43
Started
2025
with 3 others
Observational
16 of 28
6 open now
Registered
17th of 28
by date
Lead sponsor
2 of 28
Fondazione Don Carlo Gnocchi ETS

Among the 28 studies in Consciousness Disorders with a site in Italy, this one is the 6th largest by planned enrollment of the 16 observational ones that give a count, is one of 4 that started in 2025, is one of 16 observational ones, and was the 17th registered.

Consciousness Disorders

291 studies on the registry are indexed under Consciousness Disorders; 109 are open to participants now.

Browse Consciousness Disorders studies →

Open to participants now

10 of the 28 studies in Consciousness Disorders with a site in Italy are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 74 Consciousness Disorders studies recruiting now, 31 (42%) set no upper age limit and 24 (32%) stop at 75 or younger; 12 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Consciousness Disorders with a site in Italy, or all of them as a file.
02

Study summary

Differential diagnosis between Unresponsive Wakefulness Syndrome (UWS) and Minimally Conscious State (MCS) is complicated due to severe cognitive and/or sensorimotor deficits in these patients. In this study the investigators aimed at exploring the diagnostic and prognostic validity of spontaneous eye blinking parameters (rate, amplitude, duration, variability) in a sample of patients with Disorders of Consciousness (DoC).

This is a multi-center prospective observational study conducted in patients with Severe Acquired Brain Injury (sABI) and DoC admitted to 8 European participating centers, with clinical data collection not deviating from routine practice. The study is non-commercial and will have a maximum total duration of 24 months.

Read the detailed description

Observational, multicenter, longitudinal study. In this study, all patients admitted to the nine participating centers with diagnosis of DoC, and meeting the inclusion/exclusion criteria, will be enrolled.

The admission of a patient to the research program is subject to the signing of an informed consent by the legal representative/primary caregiver of the patient. The representative will be informed about the study and its objectives, and an informational sheet will be provided.

Population All patients with DoC after sABI consecutively admitted to participating centers who meet the inclusion/exclusion criteria (see below).

Sample size On the basis of the effect size found in a previous study regarding the diagnostic value of eye blink rate (d=0.68), it is planned to enroll 58 patients with DoC (power=0.8; α=0.05) + an additional 20% to cope with possible drop-outs, for a total of 70 patients (23 in UWS, 23 in MCS minus; 23 in MCS plus; about 9 patients per center). For the secondary outcomes (i.e., diagnostic and prognostic value of further blink features) there is no previous data in the literature. In addition, a sample of 23 healthy individuals, balanced in terms of sex and age with the patient sample, will be enrolled as a reference group.

Data collection procedure Within two weeks from study entry, patients will undergo two 20-minute resting electroencephalogram-electrooculogram (EEG-EOG) examinations, separated by 24 hours. Sessions will take place, following standard nursing procedures, between 10:00 AM and 5:00 PM, a time window minimally influenced by circadian peaks of drowsiness in patients with DoC, and a period during which it is believed that EBR is stable in healthy individuals.

The EEG-EOG recording will be conducted at the patient's bedside or, if possible, on their wheelchair, with the patient awake (i.e., eyes open), maintaining a quiet and dimly lit environment. If the patient's arousal level is insufficient, the Coma Recovery Scale-Revised (CRS-R) arousal facilitation protocol will be administered; if the patient continues to keep their eyes closed, the recording session will be postponed to the next available day. During each session, the experimenter is positioned beside the patient, out of her/his visual field. Blinks will be detected in the EOG and defined as a sharp positive peak followed by a negative deflection within a time window of less than 400 ms. To assess the level of consciousness at the time of the EEG-EOG recordings, a CRS-R will be administered at the end of each session. To prevent the patient's awareness of the blink recording from affecting their blink rate, the patient is not informed about the blink recording during the EEG-EOG session but is simply encouraged to remain relaxed with eyes open and not to move. This procedure is carried out independently of the patient's clinical diagnosis. A follow-up assessment is planned at 6 months from T0 (T1).

The healthy volunteers will also perform two resting EEG-EOG examinations, each lasting 20 min, 24 h apart.

EEG will be recorded by at least 19 electrodes placed on the patients' scalp according to the international 10-20 system (Fp1, Fp2, F7, F8, F3, F4, C3, C4, T3, T4, P3, P4, T5, T6, O1, O2, Fz, Cz, Pz) + vertical EOG electrodes, referenced to the vertex. Impedance will be kept below 5 kΩ for electrodes covering the cortex as well as for EOG electrodes. Data will be sampled at a 1000-Hz rate and band pass filtered between 0.1 Hz and 30 Hz; a notch filter will be used to eliminate frequencies around 50 Hz for online visualization. If the EEG recording in a session presents a considerable number of artefacts, the acquisition will be repeated within the next available day.

Enrollment duration: 12 months Study duration: about 24 months.

Statistical plan Patient characteristics at study entry will be compared between the diagnostic groups (UWS, MCS minus, MCS plus) through parametric or non-parametric univariate analyses, as deemed appropriate after verification of data distribution. Similarly, univariate analyses will be performed to compare eye blink rate (EBR) and additional blink features between diagnostic groups.

Univariate within-subject analyses will be performed to compare EBR and additional blink features across time.

In addition, correlation analyses will be performed to verify the existence of a relationship between blink features and level of consciousness as measured by the total score of the CRS-R. If so, logistic regression models will be implemented with blink features and demographic and anamnestic variables as predictors, and outcome as dependent variable. The results will be considered statistically significant if p\<05.

03

Conditions studied

  • Disorders of Consciousness

Keywords

  • Disorders of Consciousness
  • blinking
  • diagnosis
  • prognosis
  • rehabilitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients in UWS or MCS due to severe acquired brain injury with different etiology (traumatic, anoxic, vascular) consecutively admitted at participating neurorehabilitation units. The total sample will be composed of 70 patients (n=9 pts per participating unit).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical diagnosis of DoC (UWS, MCS minus, MCS plus) following repeated clinical evaluation (at least four CRS-R in a week)
  • age ≥ 18 years
  • time post-onset ≤6 months
  • Previous sABI of any etiology (traumatic, vascular, anoxic, mixed, etc.)
  • Negative anamnesis for neurological or psychiatric disorders.

Exclusion criteria

Exclusion Criteria:

  • unstable clinical conditions (e.g. respiratory failure, fever, status epilepticus, etc.);
  • ophthalmic diseases, or clinically detected peripheral damage in eyelid motility (e.g. orbital fracture);
  • intake of sedative drugs in the preceding 24 hours;
  • additional brain event following admission (e.g., stroke).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with DoC consecutively admitted to participating units and met the inclusion criteria

    Patients in VS or MCS due to severe acquired brain injury with different etiology (traumatic, anoxic, vascular) consecutively admitted at participating neurorehabilitation units. The total sample will be composed of 70 patients (n=9 pts per participating unit).

06

What researchers measure

Primary outcomes

  1. Clinical Diagnosis

    Clinical diagnosis as assessed by the Coma Recovery Scale-Revised (min. - max- score = 0-23, with higher scores indicating a higher level of consciousness)

    Time frame: 6 months from enrollment

07

Study locations

7 of 8 sites recruiting
  • Coma Science Group, GIGA-Consciousness, University of Liege
    Liège, Belgium 4000, Belgium
    Not yet recruiting
    • Olivia Gosseries, PhD · Contactogosseries@uliege.be
    • Olivia Gosseries, PhD · Principal investigator
    • Aurore Thibaut, PhD · Sub investigator
    • Youssra Mezoudi, M.Sc. · Sub investigator
  • Therapiezentrum Burgau
    Burgau, Germany 89331, Germany
    Recruiting
  • Dipartimento di Neurologia, LMU Hospital, LMU Munich
    Munich, Germany 81377, Germany
    Recruiting
  • Polo Specialistico Riabilitativo Fondazione Don Carlo Gnocchi ONLUS
    Sant'Angelo dei Lombardi, AV 83054, Italy
    Recruiting
    • Anna Estraneo, PhD · Contactaestraneo@dongnocchi.it · 3396418648
    • Alfonso Magliacano, PhD · Contactamagliacano@dongnocchi.it · 3387389414
    • Anna Estraneo, MD · Principal investigator
    • Alfonso Magliacano, PhD · Sub investigator
    • Giovanni Scarano, BS · Sub investigator
  • Unità Gravi Cerebrolesioni - Dipartimento Neuroscienze - Azienda Ospedaliera - Universitaria Ferrara
    Ferrara, Italy 44124, Italy
    Recruiting
    • Susanna Lavezzi · Contacts.lavezzi@ospfe.it
    • Susanna Lavezzi · Principal investigator
    • Valentina Bonsangue · Sub investigator
    • Sofia Straudi · Sub investigator
  • IRCCS Fondazione Don Gnocchi ONLUS
    Florence, Italy 50143, Italy
    Recruiting
    • Bahia Hakiki, PhD · Contactbhakiki@dongnocchi.it
    • Bahia Hakiki, PhD · Principal investigator
    • Andrea Mannini, PhD · Sub investigator
    • Piergiuseppe Liuzzi, PhD · Sub investigator
  • IRCCS Santa Maria Nascente Fondazione Don Gnocchi ONLUS
    Milan, Italy 20148, Italy
    Recruiting
    • Angela Comanducci, PhD · Contactacomanducci@dongnocchi.it
    • Angela Comanducci, PhD · Principal investigator
    • Tiziana Atzori · Sub investigator
    • Chiara-Camilla Derchi · Sub investigator
  • Instituto de Rehabilitación Neurológica IRENEA
    Valencia, Spain 46007, Spain
    Recruiting
    • Enrique Noé, MD · Contactenoe@comv.es
    • Enrique Noé, MD · Principal investigator
    • Roberto Llorens, PhD · Sub investigator
    • Alejandro Galvao, PhD · Sub investigator
08

References and documents

Publications

  • Wislowska M, Del Giudice R, Lechinger J, Wielek T, Heib DPJ, Pitiot A, Pichler G, Michitsch G, Donis J, Schabus M. Night and day variations of sleep in patients with disorders of consciousness. Sci Rep. 2017 Mar 21;7(1):266. doi: 10.1038/s41598-017-00323-4. PubMed 28325926 ↗
  • Barbato G, Ficca G, Muscettola G, Fichele M, Beatrice M, Rinaldi F. Diurnal variation in spontaneous eye-blink rate. Psychiatry Res. 2000 Mar 6;93(2):145-51. doi: 10.1016/s0165-1781(00)00108-6. PubMed 10725531 ↗
  • Magliacano A, Rosenfelder M, Hieber N, Bender A, Estraneo A, Trojano L. Spontaneous eye blinking as a diagnostic marker in prolonged disorders of consciousness. Sci Rep. 2021 Nov 17;11(1):22393. doi: 10.1038/s41598-021-01858-3. PubMed 34789832 ↗

Individual participant data

Plan to share: Yes — IPD will be shared upon reasonable request.

Supporting information: Study protocol

Time frame: After study completion.

Access criteria: Upon reasonable request to the study's PI.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 57 non-industry observational studies under Consciousness Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 95. This study's planned 19 months is below that.

Counting every sponsor, half of 59 studies reached it within 40 months; a quarter within 22 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2024
First posted
Mar 21, 2024
StartActual
May 8, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06323031
Lead sponsor
Fondazione Don Carlo Gnocchi ETS
Collaborators
Therapiezentrum Burgau, University of Liege, University Hospital Munich, Ludwig-Maximilians - University of Munich, VITHAS Valencia (Spain), Lavezzi Susanna, Local Health Unit, Ferrara (IT)
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
May 8, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 13, 2026

Study contacts

Anna Estraneo, MD
Contact
aestraneo@dongnocchi.it
3396418648 ext. 39
Alfonso Magliacano, PhD
Contact
amagliacano@dongnocchi.it
3387389414 ext. 39

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion